Biopharmaceutical companies sometimes get a bad rep for their pricing and marketing tactics. But there are companies working within the biopharmaceutical industry that don’t follow the more typical processes associated with their larger brethren. These are the smaller companies working in the drug development trenches. Finding one of these workhorses can be difficult, but if they are found and nursed along, a nice profit can result.
Genta Inc., a biopharmaceutical company, works to develop and market biopharmaceutical products directed at cancer and other small molecule applications. The company currently has a diverse portfolio of products at or nearing the end of trials.
The company is not one of your more typically defined biopharmaceutical companies. It is a smaller research company pursuing solutions and making progress with minimal funding. It is, however, primed to leave this status behind if it can gain approvals for its leading Genasense product. This particular product has been having issues at every step in the approvals process, but has been moving forward with trails by application rather than as an overall pharmaceutical. There does, however, appear to be positive speculation about current results.
Perhaps adding to the company’s issues with funding is the decision to market its products independently instead of in conjunction with companies having a deeper marketing budget. Whether this somewhat noble but naive decision will prove productive remains speculative, but a partner does appear to be a need at the moment. Genta Inc. has made great strides with a product designed to aide cancer cell destruction resistance, has a deep pipeline and a desire to go it alone. If it can buck a marketing trend, it stands to make a very nice profit for its efforts.
Let us hear your thoughts below:
